Led · Series B · Jul 2026

Materna Medical develops technologies addressing unmet needs in women's pelvic health, with a mission to transform the standard of care in OBGYN. Its first product, Milli, is a vaginal dilator originally launched as a wellness trainer in 2019 and cleared by the FDA in 2023 for over-the-counter sale. Milli outcomes have been studied in a post-market prospective virtual study called POMPOM. Materna's second product, Ellora, is an investigational device intended to reduce pelvic floor muscle injury during vaginal delivery and is being evaluated in the randomized EASE trial across 20 U.S. hospitals. The company recently raised $5 million in a B3 financing to support completion of the EASE trial readout, expand Milli channel access, and prepare Ellora's commercialization and manufacturing. Materna is headquartered in Mountain View, California.

Participated · Equity · Apr 2026

Route 92 Medical develops neurovascular intervention technologies for acute ischemic stroke, notably the HiPoint Reperfusion System and its Monopoint approach to improve endovascular thrombectomy efficiency. The company completed the 250-patient SUMMIT MAX randomized trial, reporting strong safety and a high first pass effect rate. After submitting those results, the HiPoint Reperfusion System received FDA clearance in May 2025 for neurothrombectomy procedures. Route 92 has reported rapid growth in product adoption and an expanding commercial organization. With $50 million in new growth financing, the company intends to accelerate global commercial expansion, build clinical evidence for broader adoption, and continue investing in product innovation. Investors cited robust manufacturing capacity and a well-differentiated product portfolio as reasons for supporting the company’s next phase of growth.

Participated · Series E · Mar 2026

Monteris Medical develops the NeuroBlate System, a robotically controlled, MR-guided laser ablation platform that enables minimally invasive treatment of brain tumors and drug-resistant epilepsy in patients aged two and older. The technology, deployed in nearly 130 health systems across North America, delivers precise laser energy to destroy abnormal brain tissue while minimizing collateral damage. Clinical studies cited by the company report short hospital stays, low complication rates, and outcomes comparable to open resection. Monteris plans to use new capital to expand its U.S. commercial footprint, advance technology development, conduct additional clinical research, and pursue geographic expansion. Management reports strong operational results with a near-term pathway to profitability and positive cash flow. The NeuroBlate platform is currently the only LITT system with a robotic interface and published prospective clinical data supporting its safety and efficacy.

Led · Series C · Aug 2023

Radiaction Medical develops a plug-and-play system that attaches to C-arm systems and proactively blocks up to 97% of scatter radiation at the source, providing head-to-toe protection while allowing unencumbered patient care and access. The technology is clinically supported by extensive lab testing and peer-reviewed, published real-world literature validating its performance in clinical settings. Radiaction has received CE Marking and FDA clearance and is currently being marketed in North America. The company is rapidly expanding its footprint in the United States by adding new sites and providing key support staff to ensure successful system installations. Radiaction is also developing additional features and growing its clinical publication pipeline to further support the technology’s performance with clinical data. Financially, the company announced a $12.6 million Series C2 financing and elected Christopher Barys to its board to support market development and growth. RadiAction Medical develops an innovative radiation shielding device for fluoroscopic systems used in interventional suites. Its device transfers radiation shielding from personnel to the fluoroscopy system while integrating with the physician’s workflow and delivering zero impact on X‑ray image quality. The solution is designed to let medical teams increase the number of image‑guided procedures performed annually, extend time in the catheterization lab, and reduce risks from X‑ray exposure. RadiAction’s technology is protected by several patents in the USA and globally. The company intends to use proceeds from its $5.7M Series A to accelerate R&D, complete required tests, obtain regulatory clearances, and bring a commercial product to market. RadiAction was founded in 2014 by Dr. Amir Belson and Jonathan Yifat in the RAD Biomed incubator in Israel and is based in Tel Aviv.

Led · Equity · Apr 2022

Koelis develops the Koelis Trinity, a system offering stand-alone ultrasound imaging and MRI fusion guidance for prostate biopsy and minimally invasive prostate cancer treatments. The Trinity features proprietary 3D ultrasound imaging and prostate motion tracking software (OBT Fusion®) to improve biopsy accuracy and enable focal treatment alternatives to whole-organ therapies. The company is running clinical-stage focal treatment programs, including the prospective multi-center Violette registry using microwave technology and a multi-center clinical evaluation of its focal cryoablation image guidance software. Koelis announced a completed follow-on €10 million growth equity financing that will support continued commercial expansion and its clinical and technology initiatives. Management states the financing will accelerate the company’s role in transforming prostate cancer diagnosis and treatment. The company presented the news in a release datelined Grenoble, France and Princeton, N.J. Koelis develops image-guided systems for diagnosis and treatment of prostate cancer, with its flagship Koelis Trinity™ platform. Trinity offers market-leading features including fusion imaging, organ tracking, robotic assistance, and focal therapy. The company’s products have received regulatory approvals and are commercialized in the United States, Europe, and most Asian markets. Koelis is based in Grenoble, France and Boston, Massachusetts, and maintains an office in Hong Kong. InnovaHealth Partners and Medevice Partners have invested in the company, with InnovaHealth acquiring a majority stake to support global growth. Management and investors expect to leverage InnovaHealth’s medtech expertise, clinician network, and capital to expand Koelis’s commercial footprint and create value.